Literatura científica selecionada sobre o tema "Sheng huo bao"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Sheng huo bao".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Sheng huo bao"
1
Hong, Mi Hyeon, Jin Seok Hwang, Byung Hyuk Han, Yun Jung Lee, Jung Joo Yoon, Chang Seob Seo, Dae Gill Kang, Hye Yoom Kim e Ho Sub Lee. "Samchulkunbi-Tang Alleviates Vascular Endothelial Disorder and Renal Dysfunction in Nitric Oxide-Deficient Hypertensive Rats". Evidence-Based Complementary and Alternative Medicine 2021 (17 de dezembro de 2021): 1–11. http://dx.doi.org/10.1155/2021/8443952.
Texto completo da fonteResumo:
Samchulkunbi-tang (SCT, Shen Zhu Jian pi tang in Chinese) is said to have been first recorded by Zheng Zhi Zhun Sheng during the Ming Dynasty in China. Records of SCT in Korea are known to have been cited in Donguibogam (Dong Yi Bao Jian in Chinese), Uibang Hwaltu (Yi Fang Huo Tao in Chinese), and Bang Yak Hapyeon (Fang Yao He Bian in China). Although SCT is widely used in treating chronic gastritis and gastric ulcers, the beneficial effect on renal vascular function is unknown. Hypertension is a risk factor for cardiovascular disease and endothelial dysfunction in humans and experimental animal models of arterial hypertension. In addition, kidney dysfunction is characterized by hypertension diseases. This study was conducted to evaluate the effect of SCT on the vascular function in vitro (human umbilical cord endothelial cells, HUVECs) and in vivo (NG‐nitro‐L‐arginine methyl ester, L-NAME-induced hypertensive rats). The phosphorylation of protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) is closely related to nitric oxide (NO) production in HUVECs, and SCT in this study significantly increased these. For three weeks, hypertensive rat models were induced by L-NAME administration (40 mg/kg/day) with portable water. It was followed by oral administration with 100 and 200 mg/kg/day for two weeks to confirm the effectiveness of SCT. As a result, systolic blood pressure decreased in the SCT-treated groups, compared with that in the L-NAME-induced hypertensive group. SCT treatment restored vasorelaxation by stimulating acetylcholine and cGMP production in the thoracic aorta. In addition, SCT treatment decreased intima-media thickness, attenuated the reduction of eNOS expression, and increased endothelin-1 expression. It also increased p-Akt and p-eNOS expression in hypertensive rat aorta. Furthermore, regarding renal function parameters, SCT ameliorated urine osmolality, urine albumin level, serum creatinine, and blood urea nitrogen levels. These results demonstrate that the oriental medicine SCT exerts potent vascular and renal protective effects on nitric oxide-deficient hypertensive rats and HUVECs
2
Tseng, Chu-Yao, Ching-Wen Huang, Hsin-Chia Huang e Wei-Chen Tseng. "Utilization Pattern of Traditional Chinese Medicine among Fracture Patients: A Taiwan Hospital-Based Cross-Sectional Study". Evidence-Based Complementary and Alternative Medicine 2018 (30 de setembro de 2018): 1–9. http://dx.doi.org/10.1155/2018/1706517.
Texto completo da fonteResumo:
Traditional Chinese medicine (TCM) divides fracture treatment into three stages. Many TCM herbs and formulas have been used to treat fractures for thousands of years. However, research regarding the Chinese herbal products (CHPs) that should be used at different periods of treatment is still lacking. This study aims to identify the CHPs that should be used at different periods of treatment as well as confirm the TCM theory of fracture periods medicine. We used prescriptions of TCM outpatients with fracture diagnoses analyzed using the Chang Gung Research Database (CGRD) from 2000 to 2015. According to the number of days between the date of the fracture and the clinic visit date, all patients were assigned to one of three groups. Patients with a date gap of 0-13 days were assigned to the early period group; those with a date gap of 14-82 days were assigned to the middle period group; and those with a date gap of 83-182 days were assigned to the late period group. We observed the average number of herbal formulas prescribed by the TCM doctor at each visit was 2.78, and the average number of single herbs prescribed was 6.47. The top three prescriptions in the early fracture period were Zheng-gu-zi-jin-dang, Shu-jing-huo-xue-tang, and Wu-ling-san. In the middle fracture period, the top three formulas were Zheng-gu-zi-jin-dang, Shu-jing-huo-xue-tang, and Zhi-bai-di-huang-wan. In the late fracture period, the top three formulas were Shu-jing-huo-xue-tang, Gui-lu-er-xian-jiao, and Du-huo-ji-sheng-tang. The main single herbs used in the early fracture period were Yan-hu-suo, Gu-sui-bu, and Dan-shen. From the middle to the late period, the most prescribed single herbs were Xu-duan, Gu-sui-bu, and Yan-hu-suo. We concluded that the results showed that the CGRD utilization pattern roughly meets the TCM theory at different fracture periods.
3
Jiang, Feng. "Mild Solutions of Neutral Semilinear Stochastic Functional Dynamic Systems with Local Non-Lipschitz Coefficients". Advances in Mathematical Physics 2013 (2013): 1–6. http://dx.doi.org/10.1155/2013/823535.
Texto completo da fonteResumo:
Semilinear stochastic dynamic systems in a separable Hilbert space often model some evolution phenomena arising in physics and engineering. In this paper, we study the existence and uniqueness of mild solutions to neutral semilinear stochastic functional dynamic systems under local non-Lipschitz conditions on the coefficients by means of the stopping time technique. We especially generalize and improve the results that appeared in Govinadan (2005), Bao and Hou (2010), and Jiang and Shen (2011).
4
Su, Wu-Chou, Li-Yuan Bai, Hui-Hua Hsiao, Her-Shyong Shiah, Yu-Min Yeh, Shang-Hung Chen, Shang-Yin Wu et al. "Abstract CT167: Trial in progress: Phase 1 dose escalation study of T-1101, a first-in-class oral Hec1/Nek2 inhibitor, in patients with advanced refractory solid tumors". Cancer Research 84, n.º 7_Supplement (5 de abril de 2024): CT167. http://dx.doi.org/10.1158/1538-7445.am2024-ct167.
Texto completo da fonteResumo:
Abstract Background: T-1101, a novel small molecule, is the first-in-class oral agent that specifically disrupts the interaction between two commonly overexpressed, critical mitotic regulators, Hec1 and Nek2, within cancer cells. Such disruption leads to abnormal mitosis followed by apoptosis of cancer cells and provides a potential therapeutic strategy for cancer treatment. T-1101, with growth inhibition concentrations (IC50) ranging from14 to 74 nM across various human cancer cell lines, exhibited potent anti-liver and breastcancer activities in vivo, and highly active (IC50 7-19 nM) in MDR (multiple drugresistance) expressing cell lines. The effective inhibitory dose of T-1101 was determined to be between 10 and 25 mg/kg twice a day in xenograft animal models. Moreover, T-1101 has synergistic activity when combined with other anticancer drugs such as doxorubicin, topotecan and paclitaxel etc. Clinically, oral powder for constitution (OPC) form was first used in the initial study. To improve better patient compliance, the capsule (CAP) form is then deployed in current T-1101’s phase 1 study. Methods: Two T-1101 oral formulations (OPC and CAP) have been designed for the first-in-human, multi-center, open-label, dose-escalation studies to evaluate the safety, tolerability and establish the Recommended Phase 2 Dose (RP2D) in subjects with advanced refractory solid tumors. The secondary objectives are to assess the pharmacokinetics (PK) and therapeutic response after receiving treatment. DLT was determined within the first treatment cycle. Patients showing clinical benefit after first 2cycles of T-1101may enter extension cohort to continue the treatment. In OPC 3+3 escalation study (NCT03195764, NCT03349073), T-1101 was administered orally once daily, days 1 to 14 every 21 days per cycle with 8 planned dose levels at dose of 9, 18, 36, 54, 72, 90, 108 to 126 mg/m2. The OPC study was terminated at 36 mg/m2 before the primary endpoint (determination of maximum tolerated dose; MTD) was reached and subsequent dosing level will be evaluated with the CAP formulation. Based on the 52% of relative oral bioavailability (%F) of CAP versus OPC in preclinical Beagle dogs’ PK study, the starting dose of CAP form of T-1101 was determined at 100 mg daily forconsecutive 28-day per cycle for 2 cycles with dose levels of 100, 200, 225, 250, 300 and 350 mg/day. The accelerated titration and Bayesian Optimal Interval (BOIN) designs are used for the T-1101 capsule dose escalation study (NCT04685473), in which one subject will be enrolled per dose level until one subject have DLT or two subjects experience ≥ Grade 2 drug-related AE during Cycle 1 at any dose level, then the dose escalation will follow the BOIN design. Cohorts 1 (100 mg/day) 2 (200 mg/day) and 3 (225 mg/day) have been completed without DLT. As of November 2023, the trial remains open to enrollment. Citation Format: Wu-Chou Su, Li-Yuan Bai, Hui-Hua Hsiao, Her-Shyong Shiah, Yu-Min Yeh, Shang-Hung Chen, Shang-Yin Wu, Hui-Ching Wang, Hui-Jen Tsai, Kwang-Yu Chang, Jui-Hung Tsai, Chun-Hui Lee, Chieh Hua Lee, Yu-Sheng Chao, Li-Tzong Chen. Trial in progress: Phase 1 dose escalation study of T-1101, a first-in-class oral Hec1/Nek2 inhibitor, in patients with advanced refractory solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT167.
5
LEE, EUN KYOUNG. "A Study on Meanings of the Synonymous Constructions ‘Qian/Hou+Yi/Ban+X’ and ‘Shang/Xia+Yi/Ban+X’: A Corpus-driven Collostructional Analysis". Journal of Chinese Studies 102 (30 de novembro de 2022): 23–55. http://dx.doi.org/10.35982/jcs.102.2.
Texto completo da fonte
6
Bao, Hua, Xiaoxi Chen, Min Wu, Shiting Tang, Xuxiaochen Wu, Wanxiangfu Tang, Dongqin Zhu et al. "Abstract 1266: Development and performance of a multi-cancer early detection test utilizing plasma cfDNA fragmentomics: A large-scale, prospective, multicenter study". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 1266. http://dx.doi.org/10.1158/1538-7445.am2024-1266.
Texto completo da fonteResumo:
Abstract Background: The implementation of the multi-cancer early detection (MCED) test offers a valuable adjunct to existing screening methods, enabling more efficient detection of cancer and potentially leading to improved treatment outcomes and prognoses for patients. Here, we report on the performance of an MCED test, which utilizes plasma cfDNA and leverages genome-wide fragmentomics-based characteristics to identify cancer signals and predict the signal origin across a diverse range of cancer types. Methods: Plasma cfDNA from evaluable blood samples was analyzed using an MCED blood test called MERCURY, a robust machine learning classifier leveraging the low-coverage whole-genome sequencing and a comprehensive set of genome-wide features derived from cfDNA fragmentomics. A carefully selected cohort of 3076 cancer patients representing 13 cancer types, in addition to 3477 healthy controls, were pre-specified into the training and internal validation sets to train and internally validate the models to assess cancer and tissue of origin (TOO). The classifier was trained to a target specificity of 99% and locked before analysis of the independent validation set. The independent validation was enrolled prospectively and consists of 1465 participants (cancer: n= 732; non-cancer: n= 733). Results: The performance metrics in the internal validation set demonstrated that the sensitivity and specificity for cancer detection were 0.865 (95% CI [0.840, 0.887]) and 0.989 (95% CI [0.980, 0.994]), respectively. These impressive results were further substantiated in the independent validation set, where the overall sensitivity and specificity were found to be 0.874 (95% CI [0.848, 0.897]) and 0.978 (95% CI [0.965, 0.987]) respectively. Notably, the sensitivity showed an incremental increase with the stage of cancer (Stage I: 0.769, 95% CI [0.708, 0.821]; Stage II: 0.840, 95% CI [0.784, 0.886]; Stage III: 0.923, 95% CI [0.874, 0.954]; Stage IV: 0.971, 95% CI [0.901, 0.995]. Regarding the TOO model, a total of 10 cancer types with more than 100 patients in the model construction cohort were considered. The TOO model achieved a prediction accuracy of 83.5% (95% CI [80.7%, 86.6%]) and 91.8% (95% CI [89.6%, 94.1%]) for the top predicted origin and the top two predicted origins, respectively, amongst the true positive cases in the independent validation set. Conclusions: In this pre-specified, large-scale study, the MCED test, utilizing cfDNA fragmentomics, demonstrates its remarkable ability to assess cancer signal with an elevated level of sensitivity and specificity across 13 distinct types of cancer. Moreover, it displays noteworthy accuracy in predicting the tissue of origin. The performances are to be further validated in a prospective cohort study (NCT06011694). Citation Format: Hua Bao, Xiaoxi Chen, Min Wu, Shiting Tang, Xuxiaochen Wu, Wanxiangfu Tang, Dongqin Zhu, Shanshan Yang, Shuang Chang, Peng He, Xiuxiu Xu, JinPeng Zhang, Yi Shen, Shuyu Wu, Ya Jiang, Sisi Liu, Xian Zhang, Xue Wu, Yang Shao. Development and performance of a multi-cancer early detection test utilizing plasma cfDNA fragmentomics: A large-scale, prospective, multicenter study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1266.
7
Li, Shang‐Jen. "Guihan Luo. Jin dai xi fang shi Hua sheng wu shi [History of Western Botanical and Zoological Studies in China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 434 pp., illus., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. ¥46 (paper)." Isis 99, n.º 2 (junho de 2008): 380–81. http://dx.doi.org/10.1086/591325.
Texto completo da fonte
8
Peng, Zhi, Hua Wang, Baorui Liu, Huiting Xu, Zhenyang Liu, Tianshu Liu, Jun Zhang et al. "Abstract CT152: A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer". Cancer Research 83, n.º 8_Supplement (14 de abril de 2023): CT152. http://dx.doi.org/10.1158/1538-7445.am2023-ct152.
Texto completo da fonteResumo:
Abstract Background: MET gene amplification is associated with poor prognosis in gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ). Savolitinib is a potent and highly selective oral MET tyrosine-kinase inhibitor. Here we reported the preliminary efficacy and safety from a phase 2 trial of savolitinib monotherapy in patients (pts) with MET-amplified advanced or metastatic GC/GEJ. (NCT04923932). Methods: Eligible pts had 2L+ GEJ or GC, with MET amplification and measurable lesions. Pts received savolitinib at 600 mg QD for body weight (BW) ≥50 kg, while 400 mg QD for BW <50 kg in 21-day cycles until disease progression or meeting other criteria for end of treatment. Savolitinib BID regimen has also been additionally explored. The primary endpoint was objective overall response rate (ORR) evaluated by Independent Review Committee (IRC). One interim analysis (IA) was pre-defined at the first 20 QD pts who had at least 2 tumor assessments. Results: As of IA, 20 pts were enrolled for QD regimen. Demographics and clinical outcomes are shown in table 1. The mean relative dose intensity of 93.07%. Median duration of exposure was 2.09 months. Confirmed ORR by IRC was 45%, and reached 50% in 16 patients with MET GCN (high) while only 1 PR was observed in 4 patients with MET GCN (low). Duration of response rate at 4-month was 85.7% with median follow up time of 5.5 months. The most common Gr≥3 TRAE (≥5%) were platelet count decreased, hypersensitivity, anemia, neutropenia and hepatic function abnormal. In all pts, only 1 patient discontinued treatment due to grade 4 liver function abnormal (TRAE) and no patient died due to TRAE. Conclusion: Savolitinib monotherapy had manageable safety and showed promising efficacy in pts with MET-amplified GEJ or GC, particularly in pts with MET high GCN. BID regimen is being investigated to further evaluate the efficacy and safety of savolitinib in pts with MET high GCN. Table 1. Pts baseline characteristics and clinical efficacy Baseline Characteristics ITT in IA (n=20) Median age (min, max), yearsSex (male/female), nECOG (0/1/2)Median BMI (min, max), (kg/m2)Primary location of tumor (GC/GEJ)Tumor stage (IV)Prior line of therapy (1/2/≥3)MET GCN (high/low) 57.00 (39.5, 76.8)17/33/15/220.8 (14.9, 25.8)16/4205/10/516/4 Clinical Efficacy By IRC By Investigator Confirmed objective response rateDisease control rate4m-DoR rate,% (95% CI) 45%65%85.7 (33.4, 97.9) 40%55%71.4 (25.8, 92.0) Citation Format: Zhi Peng, Hua Wang, Baorui Liu, Huiting Xu, Zhenyang Liu, Tianshu Liu, Jun Zhang, Yuxian Bai, Ying Yuan, Tao Wu, Feng Ye, Qinghua Pan, Jufeng Wang, Enxiao Li, Diansheng Zhong, Yueyin Pan, Yanru Qin, Yan Yang, Yusheng Wang, Aiping Zhou, Yongshun Chen, Dianbao Zhang, Hongli Liu, Xiujuan Qu, Shubin Wang, Ning Liu, Jinsheng Wu, Wei Li, Kejun Nan, Hongming Pan, Jianming Xu, Chunmei Bai, Heling Liu, Jia Wei, Runzhi Chen, Rongrong Li, Wei Li, Jinghong Zhou, Hongyan Yin, Qian Xu, Songhua Fan, Yongxin Ren, Weiguo Su, Lin Shen. A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT152.
9
Qin, Shukui, Xiaoyan Lin, Zhiqaing Meng, Zhenggang Ren, Yuxian Bai, Shanzhi Gu, Li Zheng et al. "Abstract CT150: Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)". Cancer Research 83, n.º 8_Supplement (14 de abril de 2023): CT150. http://dx.doi.org/10.1158/1538-7445.am2023-ct150.
Texto completo da fonteResumo:
Abstract Background: The mammalian target of rapamycin (mTOR) is a serine/threonine kinase related to the lipid kinases of the phosphoinositide 3-kinase (PI3K) family, which has been confirmed to be closely related to the development of a variety of human cancers. Onatasertib (ATG-008) is a 2nd generation mTOR inhibitor which inactivates both mTORC1 and mTORC2. Our previous clinical investigation (NCT01177397) has demonstrated preliminary evidence of antitumor activity of onatasertib across multiple solid and hematologic malignancies, with encouraging signals of activity in subjects with hepatitis B virus (HBV)+ unresectable, refractory HCC. Methods: Asian patients with advanced HBV+ HCC who had experienced progressive disease after at least 1 line of systemic therapy were enrolled in this study. Onatasertib was administered orally once a day (QD) at 3 dose levels (15 mg, 30 mg and 45 mg) or 20 mg twice daily (BID). The primary endpoints were pharmacokinetics (PK), safety and efficacy (NCT03591965). Results: As of July 11, 2022, 73 patients were enrolled and evaluated. The median age was 52.0 years and the median follow up duration was 26.5 months. The mean number of prior lines was 1.8. 63 patients (86.3%) had at least one Grade 3-4 treatment emergent adverse event (TEAE), and 25 (34.2%) had at least one serious adverse event (SAE). Among the 73 subjects, 3 achieved confirmed partial response (PR), all in the 45 mg QD cohort. 18 pts were enrolled in the 45 mg QD cohort, in which 11 (61.1%) pts had received at least 2 prior lines of systemic therapy and 15 (83.3%) pts had been exposed to an anti-PD-1/PD-L1 antibody. The overall response rate (ORR) in the 45 mg QD cohort was 16.7%. The median progression-free survival (mPFS) was 3.0 months (95% CI 1.9, 4.6) in the intention to treat (ITT) population and was 5.3 months (95% CI 1.9, 7.6) in the 45mg QD cohort. Median overall survival time (mOS) was not evaluable in the 45 mg QD cohort and the mOS was 13.4 months (95% CI 7.4, 19.8) in the ITT population. Onatasertib demonstrated linear pharmacokinetics between 15 mg QD and 45 mg QD in this Asian population and there was no significant exposure accumulation after multiple dosing, as previously seen in the US population. Conclusion: Onatasertib (ATG-008) showed encouraging single agent antitumor activity in patients with HBV+ advanced HCC after at least 1 prior systemic therapy, notably in the 45 mg QD dose level, in which most patients had been previously exposed to anti-PD-L1/PD-1 therapy. The results indicates that onatasertib has potential efficacy in HBV+ HCC patients who failed prior CPI treatment. Further study may be warranted, particularly in HBV+ HCC patients who have failed prior anti-VEGFR and anti-PDL1/PD-1 therapy. Citation Format: Shukui Qin, Xiaoyan Lin, Zhiqaing Meng, Zhenggang Ren, Yuxian Bai, Shanzhi Gu, Li Zheng, Qiu Li, Sun-Yong Oh, Yabing Guo, Yoong-Koo Kang, Wei-Yu Kao, Wei Li, Jung-Hwan Yoon, Helong Zhang, Pei-Jer Chen, Tsai-Sheng Yang, Jeong Heo, Zhendong Zheng, Hui Xie, Zhinuan Yu. Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT150.
10
Scesa, Federico, Eugenio Gibertini, Luca Magagnin e Maurizio Sansotera. "Surfactant-Assisted Synthesis of FeF3 • 0.33 H2o and Its Application As Cathodic Material for Electrochemical Energy Storage Devices: From Lithium to Fluoride-Ion Batteries". ECS Meeting Abstracts MA2023-02, n.º 4 (22 de dezembro de 2023): 537. http://dx.doi.org/10.1149/ma2023-024537mtgabs.
Texto completo da fonteResumo:
New generation of electrochemical energy storage devices is needed to face the continuous increase in energy stored capacity demand at lower costs from human society. Moreover, due to the constant increase in number of batteries produced, the development of more sustainable devices without the consumption of limited resources at affordable costs is an actual research challenge. The conventional lithium batteries, the most widespread kind of electrochemical energy storage devices, made by an intercalation cathode (e.g., LiCoO2, LiFePO4) and a graphite anode suffer of limited capacity for high-performance application (such as in electric vehicles) and use limited mineral resources with adverse environmental consequences. Iron fluoride is a promising conversion cathode for positive electrodes in next-gen lithium batteries due to its low cost, great abundance, and ease of extraction1,2. The main problems of metal fluoride-based cathodes are the low conductivity and the structural changes during charge/discharge cycles that limit device capacity and lifespan. To effectively increase the storage capacity, several attempts to use metal lithium anodes have been made. However, this solution is now limited to primary batteries because of dendrites growth during metal plating that causes capacity fading and safety concerns. In the last decade, batteries based on fluoride-ion shuttling are drawing attention3,4 due to the possibility to use a high-capacity conversion cathode, exploiting a multi-electron transfer, and a metal anode without dendrites formation. This kind of devices, in the early stage of development, rely on electrochemical fluorination of an electropositive metal anode and the defluorination of a more “noble” metal fluoride without a metal plating-stripping process. Nowadays, electrolyte limitation is the main challenge for the development of a fluoride-ion battery that can compete with state-of-the-art lithium-ion batteries. In this work, a surfactant-assisted solvothermal route to obtain iron fluoride hydrate (FeF3 0.33 H2O) is presented. A hierarchical grape-like structure was obtained and it was tested as cathode active material in a 2025 coin-cell working in a metal-lithium battery configuration. In these tests it showed improved performance, compared to the same synthesis without surfactant. The synthetized material was also characterized by morphological and electrochemical point of view by means of Electrochemical Impedance Spectroscopy (EIS), galvanostatic charge discharge (GCD) and cyclic voltammetry (CV). The possibility to use the same cathodic material in a room-temperature fluoride-ion battery with a metal anode was assessed by using fluoride conducting liquid electrolytes5: encouraging results about the feasibility were achieved; however, further research in the field of liquid electrolytes resulted fundamental for bringing performances of this technology to the level of actual lithium batteries. References: [1] Bai, Y.; Zhou, X.; Zhan, C.; Ma, L.; Yuan, Y.; Wu, C.; Chen, M.; Chen, G.; Ni, Q.; Wu, F.; Shahbazian-Yassar, R.; Wu, T.; Lu, J.; Amine, K. Nano Energy 2017, 32, 10–18. [2] Wei, S.; Wang, X.; Jiang, M.; Zhang, R.; Shen, Y.; Hu, H. J. Alloys Compd. 2016, 689, 945–951. [3] Reddy, M. A.; Fichtner, M. Journal of Materials Chemistry 2011, 21 (43), 17059–17062. [4] Xiao, A. W.; Galatolo, G.; Pasta, M. Joule 2021, 5 (11), 2823–2844. [5] Davis, V. K.; Bates, C. M.; Omichi, K.; Savoie, B. M.; Momčilović, N.; Xu, Q.; Wolf, W. J.; Webb, M. A.; Billings, K. J.; Chou, N. H.; others. Science 2018, 362 (6419), 1144–1148.
Teses / dissertações sobre o assunto "Sheng huo bao"
1
Li, Jiaju. "Shanghai shang wu yin shu guan yu jin dai zhi shi wen hua de chuan bo he su zao (1897 zhi 1949) cong shu ji chu ban shi jiao du kao cha /". online access from Digital dissertation consortium, 2001. http://libweb.cityu.edu.hk/cgi-bin/er/db/ddcdiss.pl?3066579.
Texto completo da fonte
2
Guan, Xiu-Hui, e 關秀惠. "The Bodily Images of Transgessing the Social System: Hou Jun–Ming’s Sou Shen Ji and Chen Jie-Ren’s Hun Po Bao Luan". Thesis, 2004. http://ndltd.ncl.edu.tw/handle/74528379868941789227.
Texto completo da fonteResumo:
碩士國立成功大學
藝術研究所
92
After the government declared that the martial law had ended, Taiwanese art became to get rid of the burden of politics and tradion and start to wear a gorgeous face gradually. New visual aesthetics which break tradional/academic representations of human bodies have gradually come into extistence.This thesis pays attention to the change, and fouses on two convulsive series of works: Hou Jun-Ming’s Sou Shen Ji and Chen Jie-Ren’s Hun Po Bao Luan. It will deeply discuss the relationship between Taiwanese art and social atmosphere by interpreting the specific bodily images of the two series of works. The main point of writing this thesis is mainly “transgression”. It attempts to analyze how Sou Shen Ji and Hun Po Bao Luan bear the artists’ recations, critical thoughts and re-interpretation against the traditional society and national power in social open atmosphere. Furthermore, I think that these two series of works have the Bataillean transgression aesthetics no matter how their forms and contents are heterogeneous. Morever, I also want to indicate these bodily images of these two series of works have grotesque characteristics, and try to analyze politics meanings of these grotesque bodily images. Lastly, I also seek to figure out how these works reflect the artists’ anxiety and desire by referring to some articles and interviews of artists intertextualily. In conclusion, I will explain the synchronic meanings of these bodily images in Taiwanese art.
3
Yeh, Hui-Man, e 葉蕙滿. "Hui- Man Yeh Graduate Concert Interpretation Report-Analysis of Bai shueh in Shen Chi Mi Pu". Thesis, 2014. http://ndltd.ncl.edu.tw/handle/8pu8xz.
Texto completo da fonte
4
HSIEH, YI-HAN, e 謝逸涵. "The Phi-pha compositions inspired by Chinese regional music：Sin-jhong-hua-liou-ban, Shuang-sheng-hen and Han-Yia-Si-Shuei". Thesis, 2010. http://ndltd.ncl.edu.tw/handle/95542157159240606993.
Texto completo da fonteLivros sobre o assunto "Sheng huo bao"
1
Liang, Fengxiang, e Liang Junxiang. Sheng huo bao de hui yi. Guangzhou Shi: Shi jie tu shu chu ban Guangdong you xian gong si, 2013.
Encontre o texto completo da fonte
2
long, Han. Wang shang xin sheng huo bao dian. Cheng dou: Dian zi ke ji ta xue chu ban she, 2004.
Encontre o texto completo da fonte
3
Qiuyun, Wei, e Pudong xin qu she qu xue yuan, eds. Pei yang bao bao liang hao sheng huo xi guan. Shanghai: Shanghai she hui ke xue yuan chu ban she, 2014.
Encontre o texto completo da fonte
4
Ray, Mills, e Jin Zhe, eds. Sheng huo Ying yu shi shang bao dian. Xianggang: Wan yuan tu shu you xian gong si, 2005.
Encontre o texto completo da fonte
5
Xiao shu miao bian ji bu., ed. Sheng huo bao jian er ge. Xianggang: Xiao shu miao jiao yu chu ban she you xian gong si, 2006.
Encontre o texto completo da fonte
6
qing, Zhong. Gu du sheng huo bao dian. Zhu hai: Zhu hai chu ban she, 1997.
Encontre o texto completo da fonte
7
Li, Ye. Jian kang cheng bao: Sheng huo bao jian hua ni zhi. Shen zhen: Hai tian chu ban she, 2004.
Encontre o texto completo da fonte
8
Xu, Jian. Yu huo chong sheng. Shenyang: Wan juan chu ban gong si, 2012.
Encontre o texto completo da fonte
9
Buxiao, Dai, ed. Zhongguo sheng huo zhi liang bao gao. Shanghai Shi: Wen hui chu ban she, 2005.
Encontre o texto completo da fonte
10
Wen, Zhuo, ed. Ri chang sheng huo bao jian fang. Shanghai: Shanghai ke xue ji shu wen xian chu ban she, 2004.
Encontre o texto completo da fonteCapítulos de livros sobre o assunto "Sheng huo bao"
1
Taber, Douglass F. "Organic Functional Group Interconversion". In Organic Synthesis. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190646165.003.0005.
Texto completo da fonteResumo:
Feng Li of the Nanjing University of Science and Technology devised (Chem. Commun. 2014, 50, 8303) a combination of reagents that directly converted the alcohol 1 to the protected amine 2. Yong-Sheng Bao and Bao Zhaorigetu of Inner Mongolia Normal University selectively (J. Org. Chem. 2014, 79, 6715) demethylated the tertiary amine 4, leading to the amide 5. Christopher W. Bielawski of the University of Texas developed (Chem. Eur. J. 2014, 20, 13487) the reagent 7 for the conversion of an alcohol 6 to the bromide 8. The diiodo analogue of 7 also worked well. Ross Denton of the University of Nottingham showed (Chem. Commun. 2014, 50, 7340) that the reagent 10 efficiently mediated the Mitsunobu coupling of 9 with benzoic acid to give 11. The other product of the reaction, Ph₃ P=O, could be converted back to 10. Silas P. Cook of Indiana University established (J. Am. Chem. Soc. 2014, 136, 9521) conditions for the selective conversion of the bromide 12 to the boronate 13. Gwilherm Evano of the Université Libre de Bruxelles converted (Chem. Commun. 2014, 50, 11907) the alkenyl iodide 14 to the nitrile 15 using acetone cyanohydrin as the nitrile anion source. Seth B. Herzon of Yale University developed (Angew. Chem. Int. Ed. 2014, 53, 7892) an improved Ru catalyst for the hydration of a terminal alkyne 16 to the aldehyde 17. Clément Mazet of the University of Geneva used (Chem. Commun. 2014, 50, 10592) an Ir catalyst for the isomerization of a 2,2-disubstituted epoxide 18 to the aldehyde 19. Laurent El Kaïm of the Ecole Polytechnique, Laurence Grimaud of UMPC, and Roland Jacquot and Philippe Marion of Solvay showed (Synthesis 2014, 46, 1802) that in the presence of glutaronitrile 21, AlCl₃ was an effective catalyst for the conversion of an acid 20 to the nitrile 22. Yi-Si Feng and Hua-Jian Xu of the Hefei University of Technology found (Org. Lett. 2014, 16, 4586) that a carboxylic acid 23 could be coupled with diphenyl disulfide under decarboxylating conditions, leading to the sulfide 24. Kenneth M. Doll of USDA Peoria observed (ACS Catal. 2014, 4, 3517) that decarboxylation of the unsaturated carboxylic acid 25 with a Ru catalyst delivered the alkene 26 as a mixture of regioisomers.
2
"Glossary Bailian Jiao White Lotus teachings baimiao paying homage at the temples ban band caijie street procession cha, ban small cymbals chi hui hold a feast for all the households chuige songs for winds chuigu shou drumers and wind players dangzi gong in frame daqu large pieces dizi transverse flute with kazoo membrane fang dengke releasing the lanterns fangshe or shishi pardon and distribution of food fang hedeng releasing the river lanterns gongche traditional notation gu large barrel drum guanshi, zan guan helper guanzi double-reed pipe guyueban, chuida ban wind-and-percussion band huahui assembly of performing troupes hui association huishou association head nanyue the southern music nao, bo large cymbals pai prelude paizi percussion pieces, cf. the melodic qupai qu pieces qupai labelled melodies shang miao going to the temple shan hui charitable associations she society she hui altar assembly shen body sheng free-reed mouth organ sheng-guan yue type of wind-and-percussion music shenghui outstanding association shifu masters tao suites wei tail xiangshou incense head xiaoqu small pieces xueshi learning the [ritual] business xuyuan make vows to the gods". In Tradition & Change Performance, 48. Routledge, 2012. http://dx.doi.org/10.4324/9780203985656-10.
Texto completo da fonteTrabalhos de conferências sobre o assunto "Sheng huo bao"
1
Xiaozhi Wang and Neil Pegg, ISSC 2022 Editors. "Proceedings of the 21st International Ship and Offshore Structures Congress VOLUME 3 Discussions". In 21st International Ship and Offshore Structures Congress Volume 3 Discussions. SNAME, 2022. http://dx.doi.org/10.5957/issc-2022-discussion-vol-3.
Texto completo da fonteResumo:
Committee I.1: Environment Alexander Babanin (Chair); Mariana Bernardino; Franz von Bock und Polach; Ricardo Campos,; Jun Ding; Sanne van Essen; Tomaso Gaggero; Maryam Haroutunian; Vanessa Katsardi; Alexander Nilva; Arttu Polojarvi; Erik Vanem; Jungyong Wang; Huidong Zhang; Tingyao Zhu Floor Discussers: Florian Sprenger; Carlos Guedes Soares; Henk den Besten Committee I.2: Loads Ole Andreas Hermundstad (Chair); Shuhong Chai; Guillaume de Hauteclocque; Sheng Dong; Chih-Chung Fang; Thomas B. Johannessen; Celso Morooka; Masayoshi Oka; Jasna Prpić-Oršić; Alessandro Sacchet; Mahmud Sazidy; Bahadir Ugurlu; Roberto Vettor; Peter Wellens Official Discusser: Hayden Marcollo Committee II-1: Quasi-Static Response James Underwood (Chair); Erick Alley; Jerolim Andrić Dario Boote; Zhen Gao; Ad Van Hoeve; Jasmin Jelovica; Yasumi Kawamura; Yooil Kim; Jian Hu Liu; Sime Malenica; Heikki Remes; Asokendu Samanta; Krzysztof Woloszyk; Deqing Yang Official Discusser: Prof. T. Yoshikwa Committee II.2: Dynamic Response Gaute Storhaug (Chair); Daniele Dessi; Sharad Dhavalikar; Ingo Drummen; Michael Holtmann; Young-Cheol Huh; Lorenzo Moro; Andre Paiva; Svein Sævik; Rong-Juin Shyu; Shan Wang; Sue Wang; WenWei Wu; Yasuhira Yamada; Guiyong Zhang Floor Discussers: Ling Zhu; Tomoki Takami; Anriette (Annie) Bekker; Bruce Quinton; Robert Sielski Committee III.1: Ultimate Strength Paul E. Hess (Chair); Chen An; Lars Brubak; Xiao Chen; Jinn Tong Chiu; Jurek Czujko; Ionel Darie; Guoqing Feng; Marco Gaiotti; Beom Seon Jang; Adnan Kefal; Sukron Makmun; Jonas Ringsberg; Jani Romanoff; Saad Saad-Eldeen; Ingrid Schipperen; Kristjan Tabri; Yikun Wang; Daisuke Yanagihara Official Discusser: Jørgen Amdahl Committee III.2: Fatigue and Fracture Yordan Garbatov (Chair); Sigmund K Ås; Henk Den Besten; Philipp Haselbach; Adrian Kahl; Dale Karr; Myung Hyun Kim; Junjie Liu; Marcelo Igor Lourenço de Souza; Wengang Mao; Eeva Mikkola; Naoki Osawa; Fredhi Agung Prasetyo; Mauro Sicchiero; Suhas Vhanmane; Marta Vicente del Amo; Jingxia Yue Official Discusser Weicheng Cui Floor Discussers: Robert Sielski; Sören Ehlers; Stephane Paboeuf; Teresa Magoga Committee IV.1: Design Principles and Criteria Matthew Collette (Chair); Piero Caridis; Petar Georgiev; Torfinn Hørte; Han Koo Jeong; Rafet emek Kurt; Igor Ilnytskiy; Tetsuo Okada; Charles Randall; Zbigniew Sekulski; Matteo Sidari; Zhihu Zhan; Ling Zhu Official Discusser: Enrico Rizzuto Committee IV.2: Design Methods Andrea Ivaldi (Chair); Abbas Bayatfar; Jean-David Caprace; Gennadiy Egorov; Svein Erling Heggelund; Shinichi Hirakawa; Jung Min Kwon; Dan Mcgreer; Pero Prebeg; Robert Sielski; Mark Slagmolen; Adam Sobey; Wenyong Tang; Jiameng Wu Official Discusser: Mario Dogliani Committee V.1: Accidental Limit States Bruce Quinton; Gaetano De Luca; Topan Firmandha; Mihkel Körgesaar; Hervé Le Sourne; Ken Nahshon; Gabriele Notaro; Kourosh Parsa; Smiljko Rudan; Katsuyuki Suzuki; Osiris Valdez Banda; CareyWalters; Deyu Wang; Zhaolong Yu Official Discusser: Manolis Samuelides Committee V.2: Experimental Methods Sören Ehlers (Chair); Nagi Abdussamie; Kim Branner; ShiXiao Fu; Martijn Hoogeland; Kari Kolari; Paul Lara; Constantine Michailides; Hideaki Murayama; Cesare Rizzo; Jung Kwan Seo; Patrick Kaeding Official Discusser: Giles Thomas Committee V.3: Materials and Fabrication Technology Lennart Josefson (Chair); Konstantinos Anyfantis; Bianca de Carvalho Pinheiro; Bai-Qiao Chen; Pingsha Dong; Nicole Ferrari; Koji Gotoh; James Huang; Matthias Krause; Kun Liu; Stephane Paboeuf; Stephen van Duin; Fang Wang; Albert Zamarin Official Discusser: Frank Roland Floor Discussers Alessandro Caleo; Agnes Marie Horn; Krzysztof Woloszyk; Robert Sielski Committee V.4: Offshore Renewable Energy Atanasios Kolios (Chair); Kyong-Hwan Kim; Chen Hsing Cheng; Elif Oguz; Pablo Morato; Freeman Ralph; Chuang Fang; Chunyan Ji; Marc Le Boulluec; Thomas Choisnet; Luca Greco; Tomoaki Utsunomiya; Kourosh Rezanejad; Charles Rawson; Jose Miguel Rodrigues Official Discusser: Amy Robertson Committee V.5: Special Vessels Darren Truelock (Chair); Jason Lavroff; Dustin Pearson; Zbigniew (Jan) Czaban; Hanbing Luo; Fuhua Wang; Ivan Catipovic; Ermina Begovic; Yukichi Takaoka; Claudia Loureiro; Chang Yong Song; Esther Garcia; Alexander Egorov; Jean-Baptiste Souppez; Pradeep Sensharma; Rachel Nicholls-Lee Official Discusser: Jaye Falls Floor Discussers: Jasmin Jelovica; Stephane Paboeuf; Sören Ehlers Committee V.6: Ocean Space Utilization Sebastian Schreier (Chair); Felice Arena; Harry Bingham; Nuno Fonseca; Zhiqiang Hu; Debabrata Karmakar; Ekaterina Kim; Hui Li; Pengfei Liu; Motohiko Murai; Spiro J Pahos; Chao Tian; George Wang Official Discusser: Hideyuki Suzuki Floor Discussers: Robert Sielski; Sue Wang; Sarat Mohapatra; Gaute Storhaug; Henk den Besten Committee V.7: Structural Longevity Iraklis Lazakis (Chair); Bernt Leira; Nianzhong Chen; Geovana Drumond; Chi-Fang Lee; Paul Jurisic; Bin Liu; Alysson Mondoro; Pooria Pahlavan; Xinghua Shi; Ha Cheol Song; Tadashi Sugimura; Christian Jochum; Tommaso Coppola Official Discusser: Timo de Beer Floor Discusser: Krzysztof Woloszyk Committee V.8: Subsea Technology Agnes Marie Horn (Chair); Tauhid Rahman; Ilson Pasqualino; Menglan Duan; Zhuang Kang; Michael Rye Andersen; Yoshihiro Konno; Chunsik Shim; Angelo Teixeira; Selda Oterkus; Blair Thornton; Brajendra Mishra Official Discusser: Segen F. Estefen